Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc is a biopharmaceutical company that specializes in developing innovative medicines for the treatment of cancer and rare genetic diseases. The company's research is focused on cellular metabolism, a promising field that has the potential to unlock new treatments for a range of diseases. Agios has a robust pipeline of drug candidates that target specific metabolic pathways, including IDH1 and IDH2 mutations, which are found in certain types of cancer. Its lead product, Tibsovo, is approved for the treatment of acute myeloid leukemia (AML) with an IDH1 mutation. Agios is also developing other potential treatments for AML, solid tumors, and genetic diseases such as sickle cell anemia and thalassemia. The company is dedicated to advancing the science of cellular metabolism and bringing new therapies to patients in need.